Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights a strategic collaboration with Astellas and positive Phase I data for VIR-5500, which are positive factors. However, the financial performance shows a significant decline in revenue and net income, primarily due to reduced demand for COVID-19 treatments, which negatively impacts sentiment. The increased R&D expenses indicate ongoing investment but also contribute to lower profitability. The Q&A section lacks clarity, which doesn't help improve sentiment. Overall, the mixed signals from strategic developments and financial setbacks result in a neutral sentiment.
Key Financial Performance
Revenue $150 million, a decrease of 25% year-over-year, primarily due to reduced demand for COVID-19 treatments.
Net Income $30 million, down 40% year-over-year, attributed to increased R&D expenses and lower revenue.
R&D Expenses $70 million, an increase of 20% year-over-year, driven by expanded clinical trials and strategic collaborations.
Operating Cash Flow $50 million, a decline of 15% year-over-year, due to higher operational costs and lower revenue.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VIR-5500 Strategic Collaboration: Announced a strategic collaboration with Astellas for the PSMA-targeted T-cell engager, VIR-5500.
Phase I Data for VIR-5500: Reported positive Phase I data for VIR-5500, which will be presented at ASCO-GU.
Strategic Collaboration with Astellas: Entered into a strategic collaboration with Astellas for the development of VIR-5500, focusing on PSMA-targeted T-cell engagement.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges substantial risks and uncertainties associated with forward-looking statements, which could impact clinical development programs, collaboration outcomes, and future results.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
VIR-5500 Strategic Collaboration with Astellas: Announced a strategic collaboration with Astellas for the PSMA-targeted T-cell engager, VIR-5500.
Phase I VIR-5500 Data: Reported positive Phase I data for VIR-5500, which will be presented at ASCO-GU.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Biotechnology conference
BofA Securities
CFO Kyuwon
Chazaro Cortes
Clarissa Ruiz
Collaboration Positive
Cortes Evercore
Darout Barclays
Division Alec
Division Etzer
Division Mario
Division Patrick
Division Roanna
Division Sean
Division Ulz
Division afternoon
EST Marianne
Etzer Darout
Executive VP
Head Investor
Inc Research
Instructions Head
Jason OByrne
Kiki
Kyuwon Choi
LLC Research
Marianne De
Mario Chazaro
McCutcheon Raymond
Officer Jason
PM EST
Research Division
VIR Transcript
Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript
Unknown2-24
The earnings call summary highlights a strategic collaboration with Astellas and positive Phase I data for VIR-5500, which are positive factors. However, the financial performance shows a significant decline in revenue and net income, primarily due to reduced demand for COVID-19 treatments, which negatively impacts sentiment. The increased R&D expenses indicate ongoing investment but also contribute to lower profitability. The Q&A section lacks clarity, which doesn't help improve sentiment. Overall, the mixed signals from strategic developments and financial setbacks result in a neutral sentiment.
Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call presents a mixed picture. The company's financial health appears strong, with reduced operating expenses and a cash runway extending into 2027. However, there are concerns about the lack of specific guidance on key clinical data and the heavy reliance on strategic partnerships. While the Q&A section reveals optimism about upcoming data releases, the absence of concrete targets and timelines introduces uncertainty. The market cap suggests moderate volatility, leading to a neutral prediction for stock price movement.
Vir Biotechnology, Inc. (VIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-16
Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript
Positive8-6
The earnings call summary and Q&A reveal positive indicators: successful initiation of the ECLIPSE program, significant market opportunity in HDV, and a strong cash position. Despite a net loss, lower operating expenses and a solid cash runway are promising. The Q&A indicates progress in clinical trials and competitive advantages in the hepatitis delta space. Although management was unclear on some specifics, the overall sentiment and strategic advancements suggest a positive stock movement in the short term.
VIR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
